Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.
about
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenanceHematopoietic progenitor cell collection after autologous transplant for multiple myeloma: low platelet count predicts for poor collection and sole use of resulting graft enhances risk of myelodysplasia.Isolated clonal cytogenetic abnormalities after high-dose therapy.Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide.Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia.Second malignancies after multiple myeloma: from 1960s to 2010s.Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years.Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalitiesTime trend of multiple myeloma and associated secondary primary malignancies in Asian patients: a Taiwan population-based study.The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma.The risk of secondary primary malignancies after therapy for multiple myeloma.Secondary malignancies in patients with multiple myeloma, Waldenström macroglobulinemia and monoclonal gammopathy of undetermined significance.Second primary malignancies in multiple myeloma: an overview and IMWG consensus.Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma.Therapy-related myeloid malignancies in myelomaSecondary primary malignancies in multiple myeloma: an old NEMESIS revisited.Partial remission of acute myeloid leukemia complicating multiple myeloma following COAP chemotherapy: A case report.Myelopoiesis dysregulation associated to sustained APRIL production in multiple myeloma-infiltrated bone marrow.Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols.Second primary malignancies and myeloma therapy: fad or fact?Guidelines for screening and management of late and long-term consequences of myeloma and its treatment.Treatment-related acute granulocyte-monocytic leukemia from multiple myeloma: A case report and literature review.Lenalidomide consolidation treatment in patients with multiple myeloma suppresses myelopoieses but spares erythropoiesis.Immunophenotypic alterations of bone marrow myeloid cell compartments in multiple myeloma patients predict for myelodysplasia-associated cytogenetic alterations
P2860
Q24610430-8DDE3D72-B365-490F-8580-D870319A3E71Q33731691-A4AA27E4-7C36-461B-AAD4-53E31262F6F5Q34108964-B1217CE4-1B80-4542-BB4B-89A29CBE9DDAQ34399099-7F1A7A45-DDD6-499A-93FE-59779792EED5Q34964597-3C6DCC1C-AAEA-43A3-8FE8-43D274AE1622Q35891594-E5408CD1-6A80-4EDA-A8AF-BDE5003BD290Q36115686-C920E71D-FD2C-4E35-8245-141C901038E3Q36366988-E0F30FBA-42DA-4B76-8CF2-E6A374766320Q36907852-544689F1-1799-4E04-8823-47471D08E978Q36941047-3017815A-BCF8-41DE-83EC-6CD9F80C2BF5Q36976375-DED0C32B-2AE5-4D3F-9EB7-AD6862E9E304Q37946246-EFF0438F-A459-40EC-88D2-7B01F53E67F8Q38462594-69FC4770-0C16-48DA-A49C-9F6D4775B4E4Q38933428-ED750802-A41C-40CC-919E-0DF9A12E7BBCQ39013620-19C178C8-1A49-4F13-B09F-5A05216DED14Q39129413-0E6D229B-1EF4-4428-BB0B-D5B856B078D2Q39209765-2E3AF096-650B-4C8B-B609-370B54A602A2Q39576312-497177D2-B37C-421F-8D7D-47B9AAC930DEQ40170328-D4CE3009-8485-4254-8F50-457ACE9BFBB0Q41261844-B879FEC4-1005-4273-9876-EFE4DC011FD5Q42679067-61F39B1D-D527-4982-82E5-D40DD575297AQ43155846-3AFB0F41-6C10-4E0A-8D65-FB5A976AA88AQ47587127-050B5C00-EEB1-4A9C-8039-79932B14FA81Q49487177-79C2F574-861B-4C91-9E80-4BCB7690275FQ51656403-1B6A65E2-CECF-483F-A2AD-B2D702005982Q58010072-C1341B50-C28D-4ACF-8E4D-4B211805067F
P2860
Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Cytogenetically defined myelod ...... 0 patients treated since 1989.
@ast
Cytogenetically defined myelod ...... 0 patients treated since 1989.
@en
type
label
Cytogenetically defined myelod ...... 0 patients treated since 1989.
@ast
Cytogenetically defined myelod ...... 0 patients treated since 1989.
@en
prefLabel
Cytogenetically defined myelod ...... 0 patients treated since 1989.
@ast
Cytogenetically defined myelod ...... 0 patients treated since 1989.
@en
P2093
P2860
P50
P1433
P1476
Cytogenetically defined myelod ...... 0 patients treated since 1989.
@en
P2093
Abid Mohiuddin
Guido Tricot
James Waldron
Jeff Haessler
Jeffrey Sawyer
John Crowley
Klaus Hollmig
Mauricio Pineda-Roman
Michele Cottler-Fox
Raymond Thertulien
P2860
P304
P356
10.1182/BLOOD-2007-06-097444
P407
P577
2007-09-25T00:00:00Z